A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastomaVerónica Rendo, Rameen Beroukhim, Eudocia Q. Lee et al.|Science Translational Medicine|2025Cited by 13
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analysesAlexander Ling, Patrick Y. Wen, Ryuhjin Ahn et al.|Science Translational Medicine|2025Cited by 12